US2017056380A1PendingUtilityA1

Systems, Methods, Techniques, and Compounds in Research and Treatment of Portal Hypertension and other Conditions

30
Individually held — no corporate assignee on recordPriority: Dec 31, 2013Filed: Nov 10, 2016Published: Mar 2, 2017
Est. expiryDec 31, 2033(~7.4 yrs left)· nominal 20-yr term from priority
Inventors:Don C. RockeySongling LiuGlenn Cornett
A61K 31/4355
30
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

Methods and compounds for research and treatment of portal hypertension. The use of racemic or non-racemic mixtures of furopyridine isomers to stimulate eNOS function in sinusoidal endothelial cells and to increase NO production in both normal sinusoidal endothelial cells and injured endothelial cells.

Claims

exact text as granted — not AI-modified
What is claimed is: 
     
         1 . A method of treating hepatic disorders by administration of therapeutically effective amounts of cicletanine. 
     
     
         2 . The method of  claim 1  wherein the disorder includes cirrhosis. 
     
     
         3 . The method of  claim 1  wherein the disorder includes NASH (non-alcoholic steatohepatitis). 
     
     
         4 . The method of  claim 1  wherein the disorder includes NAFLD (non-alcoholic fatty liver disease). 
     
     
         5 . The method of  claim 1  wherein the disorder includes hepatitis. 
     
     
         6 . The method of  claim 1  further including increasing endothelial nitric oxide synthase (eNOS) activity (through phosphorylation at Ser-1179) via protein kinase B (Akt) and MAP kinase/Erk signaling with administration of cicletanine. 
     
     
         7 . The method of  claim 1  wherein the disorder includes insulin resistance. 
     
     
         8 . The method of  claim 1  wherein the disorder includes elevated alanine aminotransferase (ALT) or aspartate aminotransferase (AST). 
     
     
         9 . A method of treating hepatic disorders associated with endothelial dysfunction by administration of therapeutically effective amounts of cicletanine. 
     
     
         10 . The method of  claim 9  wherein the disorder includes cirrhosis. 
     
     
         11 . The method of  claim 9  wherein the disorder includes NASH (non-alcoholic steatohepatitis). 
     
     
         12 . The method of  claim 9  wherein the disorder includes NAFLD (non-alcoholic fatty liver disease). 
     
     
         13 . The method of  claim 9  wherein the disorder includes hepatitis. 
     
     
         14 . The method of  claim 9  wherein the disorder includes insulin resistance. 
     
     
         15 . The method of  claim 9  wherein the disorder includes elevated alanine aminotransferase (ALT) or aspartate aminotransferase (AST). 
     
     
         16 . The method of  claim 9  further including increasing endothelial nitric oxide synthase (eNOS) activity (through phosphorylation at Ser-1179) via protein kinase (Akt) and MAP kinase/Erk signaling with administration of cicletanine. 
     
     
         17 . A method of increasing endothelial nitric oxide synthase (eNOS) activity (through phosphorylation at Ser-1179) via protein kinase B (Akt) and MAP kinase/Erk signaling by administration of therapeutically effective amounts of cicletanine. 
     
     
         18 . The method of  claim 17  wherein the disorder includes cirrhosis. 
     
     
         19 . The method of  claim 17  wherein the disorder includes NASH (non-alcoholic steatohepatitis). 
     
     
         20 . The method of  claim 17  wherein the disorder includes insulin resistance.

Join the waitlist — get patent alerts

Track US2017056380A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.